DKSH has officially entered into a definitive strategic distribution and commercialization partnership with BridgeBio, a U.S. biotechnology innovator focused on genetic diseases. Under the structural terms of the agreement, DKSH Business Unit Healthcare will assume full operational responsibility for supporting regulatory evaluations, market entry logistics, and commercial distribution of an investigational Transthyretin Stabilizer across Australia, Singapore, South Korea, and Taiwan. The alliance combines BridgeBio’s biotech innovation with DKSH’s integrated end-to-end commercialization platform to introduce a novel specialized treatment option to underserved regional patient populations.
The documented clinical indications, disease severity profiles, and integrated market expansion strategies feature:
-
Clinical Profiles and the Pathological Burden of ATTR-CM:
-
Therapeutic Parameters: Upon securing formal regulatory clearances within the designated territories, the transthyretin stabilizer is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adult cohorts. The clinical objective of the biologic intervention is to systematically reduce cardiovascular mortality and cardiovascular-related hospitalization rates.
-
Current Regulatory Stature: ATTR-CM operates as a progressive, debilitating, and fatal disease that severely diminishes patient quality of life and drives recurrent, intensive hospitalizations. The therapeutic molecule is not currently approved for commercial use within the countries covered by this agreement; any downstream market deployment remains strictly subject to applicable localized statutory approvals and healthcare regulations.
-
-
End-to-End Solutions and Platform Execution by DKSH Healthcare:
-
Commercial Infrastructure Deployment: Operating as a leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health, and medical device companies, DKSH will mobilize its full spectrum of integrated commercial solutions to prioritize patient access. The enterprise will deploy its specialized expertise across vital operational domains, including regulatory affairs, medical affairs, market access, and launch excellence pipelines, backed by its robust regional distribution infrastructure.
-
Strategic Growth Metrics: Patrik Grande, Global Head of Business Unit Healthcare at DKSH, noted that the strategic compact with BridgeBio represents an important milestone establishing a renewed vision for corporate growth. By blending BridgeBio’s scientific innovation with DKSH’s market expertise and trusted execution capabilities across complex national healthcare frameworks, the provider is positioned to launch this biotech innovation and expand access to critical new treatment modalities reliably, responsibly, and at scale, advancing its global mission of delivering “Healthcare for All.”
-